ACHE and early-onset autosomal dominant Alzheimer disease: Acetylcholinesterase-inhibiting therapies have greatly increased as a result of NA release, which can be used for the management of oxidative stress and neurotransmitter dysregulation caused by Alzheimer's disease through increasing acetylcholinesterase levels in the brain, though to a lesser extent than NAs (Singh et al., 2012).